Summary by Moomoo AI
ZyVersa Therapeutics, Inc., a biopharmaceutical company, has announced the completion of a 1-for-10 reverse stock split of its common stock, effective April 25, 2024. The reverse stock split was previously approved by the company's stockholders during a Special Meeting held on April 17, 2024, where they granted the board of directors the authority to determine the exact split ratio and timing. The board of directors subsequently approved the reverse stock split at the 1-for-10 ratio. Following the split, the common stock began trading on The Nasdaq Capital Market on a split-adjusted basis from market open on April 26, 2024. The par value and other terms of the common stock remain unchanged. The company's post-split common stock CUSIP number is 98987D 300. The amendment to the company's Second Amended and Restated Certificate of Incorporation, detailing the reverse stock split, was filed with the Secretary of State of Delaware and is included as Exhibit 3.1 in the current report.